Impact Biomedical (IBO) FCF Margin (2025 - 2026)
Impact Biomedical (IBO) posted FCF Margin of 6628.57% for Q1 2026, down 94.64% on a QoQ basis from 3405.56% in Q3 2025.
Impact Biomedical (IBO) FCF Margin (2025 - 2026) Analysis & Trends
Impact Biomedical's FCF Margin history runs 2 years deep, the most recent figure standing at 6628.57% for Q1 2026.
- Quarterly FCF Margin changed N/A year-over-year to 6628.57% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 5225.0% (changed N/A YoY) and the FY2022 annual result came in at 5036.0%, changed N/A from the prior year.
- FCF Margin was 6628.57% for Q1 2026 at Impact Biomedical, down from 3405.56% in the prior quarter.
- Across five years, FCF Margin topped out at 3405.56% in Q3 2025 and bottomed at 9914.29% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Impact Biomedical | 47.44 Mn | 50.67 Mn | - | -6,628.57% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6,628.57% |
| Sep 30, 2025 | -3,405.56% |
| Jun 30, 2025 | -9,914.29% |